Clinical trial · Interventional
Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma
Multicentric Study About Treatment of High Grade Peripheral T Cell Lymphoma in Adults. LTP Study Comparison Between VIP ABVD Versus CHOP
NCT00970385CI-TRIAL-00002607LTPcompletedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multicenter randomized trial evaluating induction treatment with VIP-reinforced-ABVD (VIP-rABVD) versus CHOP/21 in patients with newly diagnosed peripheral T cell lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Peripheral T Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CHOP21 | Drug | — | UNRESOLVED |
| Radiotherapy consolidation | Radiation | — | UNRESOLVED |
| VIP/ABVD | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- CHOP 21
- description
- Induction therapy CHOP every 21 days: * cyclophosphamide 750 mg/m2 intravenously (IV) day 1 * doxorubicin 50 mg/m2 IV day 1 * vincristine 1,4 mg/m2 (maximum 2 mg) day 1 * prednisone 100 mg/m2/D from D1 to D5.
- interventionNames
- Drug: CHOP21
- Radiation: Radiotherapy consolidation
- type
- EXPERIMENTAL
- label
- VIP/ABVD arm
- description
- VIP cycle: * etoposide 100 mg/m2/D IV from D1 to D3 * ifosfamide 1000 mg/m2/D from D1 to D5 * cisplatin 20 mg/m2/D as a continuous infusion from D1 to D5 ABVD cycle: * doxorubicin50 mg/m2/D on D1 and D14 * bleomycin 10 mg/m2/D * vinblastine 10 mg/m2/D * dacarbazine 375 mg/m2/D Each alternating cycle was repeated three times for a total of 6 cycles (3 VIP, 3 rABVD).
- interventionNames
- Drug: VIP/ABVD
- Radiation: Radiotherapy consolidation
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * newly diagnosed untreated PTCL * age 18 and 70 years * performance status ≤ 2 * Ann Arbor stage I to IV * normal cardiac ventricular ejection fraction over 50% * normal hepatic function (asat, ALAT, PAL \< 2.5 ULN) Exclusion Criteria: * cutaneous form of PTCL * previous treatment * age \< 18 and \> 70 * performance status \> 2 * abnormal cardiac or hepatic functions * HIV-, HCV- or HBV- positivity
References
Publications (0)
Data not yet available
No reference posted for this study.